Dicerna Pharmaceuticals, Inc. (DRNA): Price and Financial Metrics
DRNA Price/Volume Stats
| Current price | $38.22 | 52-week high | $40.14 |
| Prev. close | $38.00 | 52-week low | $19.06 |
| Day low | $38.21 | Volume | 5,568,900 |
| Day high | $38.24 | Avg. volume | 1,344,033 |
| 50-day MA | $30.08 | Dividend yield | N/A |
| 200-day MA | $28.68 | Market Cap | 2.99B |
DRNA Stock Price Chart Interactive Chart >
Dicerna Pharmaceuticals, Inc. (DRNA) Company Bio
Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. The company was founded in 2006 and is based in Cambridge, Massachusetts.
Latest DRNA News From Around the Web
Below are the latest news stories about Dicerna Pharmaceuticals Inc that investors may wish to consider to help them evaluate DRNA as an investment opportunity.
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals AcquisitionLEXINGTON, Mass., December 28, 2021--Novo Nordisk today announced that the acquisition of Dicerna, announced on 18 November 2021, has been completed. |
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire DicernaLEXINGTON, Mass., December 25, 2021--Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna |
MainStay VP Wellington Small Cap Portfolio Buys iShares Russell 2000 Growth ETF, United Natural ...Investment company MainStay VP Wellington Small Cap Portfolio (Current Portfolio) buys iShares Russell 2000 Growth ETF, United Natural Foods Inc, Mimecast, Insperity Inc, Chesapeake Energy Corp, sells Ollie's Bargain Outlet Holdings Inc, Apellis Pharmaceuticals Inc, Children's Place Inc, Hostess Brands Inc, Boston Beer Co Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, MainStay VP Wellington Small Cap Portfolio. |
Sumitomo Mitsui Trust Holdings Inc. Trims Stock Position in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)Sumitomo Mitsui Trust Holdings Inc. lessened its position in shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) by 94.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,901 shares of the biopharmaceutical companys stock after selling 432,596 shares during the quarter. Sumitomo Mitsui Trust Holdings [] |
-$0.44 EPS Expected for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) This QuarterEquities analysts forecast that Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will report earnings of ($0.44) per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Dicerna Pharmaceuticals earnings. The highest EPS estimate is ($0.04) and the lowest is ($0.99). Dicerna Pharmaceuticals reported earnings per share of ($0.49) during the same quarter last [] |
DRNA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 30.13% |
| 5-year | 187.15% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 0.00% |
| 2019 | 106.08% |
Continue Researching DRNA
Want to do more research on Dicerna Pharmaceuticals Inc's stock and its price? Try the links below:Dicerna Pharmaceuticals Inc (DRNA) Stock Price | Nasdaq
Dicerna Pharmaceuticals Inc (DRNA) Stock Quote, History and News - Yahoo Finance
Dicerna Pharmaceuticals Inc (DRNA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...